'We're not doing 30 bets a year': Vijay Pande on betting small after running $4B at a16z

Summary

Vijay Pande, who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC, discusses why biology is finally shifting from a 'discovery' science to an 'engineering' one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.